1
|
Rulli A, Listorti C, Foglietta J, Burattini M, Caracappa D, Palumbo I, Barberini F, Covarelli P, Boselli C. Impact of genetic signature on breast cancer therapy: preliminary experience. Minerva Med 2015; 106:309-313. [PMID: 26649813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- A Rulli
- Breast Unit, Department of Surgical Oncology, University of Perugia, Perugia, Italy -
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Rondelli F, Reboldi P, Rulli A, Barberini F, Guerrisi A, Izzo L, Bolognese A, Covarelli P, Boselli C, Becattini C, Noya G. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis. Int J Colorectal Dis 2009; 24:479-88. [PMID: 19219439 DOI: 10.1007/s00384-009-0662-x] [Citation(s) in RCA: 143] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/20/2009] [Indexed: 02/04/2023]
Abstract
BACKGROUND Sphincter-saving surgery for the treatment of middle and low rectal cancer has spread considerably when total mesorectal excision became standard treatment. In order to reduce leakage-related complications, surgeons often perform a derivative stoma, a loop ileostomy (LI), or a loop colostomy (LC), but to date, there is no evidence on which is the better technique to adopt. METHODS We performed a systematic review and meta-analysis of all randomized controlled trials until 2007 and observational studies comparing temporary LI and LC for temporary decompression of colorectal and/or coloanal anastomoses. Clinically relevant events were grouped into four study outcomes: general outcome measures: dehydratation and wound infection GOM construction of the stoma outcome measures: parastomal hernia, stenosis, sepsis, prolapse, retraction, necrosis, and hemorrhage closure of the stoma outcome measures: anastomotic leak or fistula, wound infection COM, occlusion and hernia functioning of the stoma outcome measures: occlusion and skin irritation. RESULTS Twelve comparative studies were included in this analysis, five randomized controlled trials and seven observational studies. Overall, the included studies reported on 1,529 patients, 894 (58.5%) undergoing defunctioning LI. LI reduced the risk of construction of the stoma outcome measure (odds ratio, OR = 0.47). Specifically, patients undergoing LI had a lower risk of prolapse (OR = 0.21) and sepsis (OR = 0.54). LI was associated with an excess risk of occlusion after stoma closure (OR = 2.13) and dehydratation (OR = 4.61). No other significant difference was found for outcomes. CONCLUSION Our overview shows that LI is associated with a lower risk of construction of the stoma outcome measures.
Collapse
Affiliation(s)
- F Rondelli
- Department of General and Oncologic Surgery, University of Perugia, Perugia, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Aristei C, Palumbo I, Cucciarelli F, Cavalli A, Tarducci R, Raymondi C, Perrucci E, Cavaliere A, Latini P, Rulli A. Partial breast irradiation with interstitial high-dose-rate brachytherapy in early breast cancer: Results of a phase II prospective study. Eur J Surg Oncol 2009; 35:144-50. [DOI: 10.1016/j.ejso.2008.06.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2008] [Revised: 05/22/2008] [Accepted: 06/02/2008] [Indexed: 10/21/2022] Open
|
4
|
Robuffo I, Fazii P, Rulli A, Di Nicola M, Toniato E, Di Rienzo M, Cosentino L, Gambi A, Castellani ML, Martinotti S. Upgraded diagnostic value of Gen-Probe PACE 2 assay for detection of Chlamydia trachomatis infection. J BIOL REG HOMEOS AG 2008; 22:253-261. [PMID: 19036228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
In this study, we evaluate the performance of a nucleic acid amplification assay, COBAS AMPLICOR (Roche Molecular systems) (PCR), compared to non-amplified DNA probe assay PACE2 (Gen-Probe Inc.) for the detection of C. trachomatis in a total of 2,916 samples (2,114 females and 802 males) consecutively collected in two different clinical pathology laboratories, over a period of three years. In the females, the endocervical swabs showed a similar range of detection when using the two different methods: out of 1,581 females processed with PACE 2, 1.4% (2005), 0.9% (2006), 0.5% (2007), resulted positive for C. trachomatis; out of 533 females processed with PCR, 1.3% (2005), 1.5% (2006) and 1.2% (2007), resulted positive. However, in the male subjects we found an increased positivity of Chlamydia detection on urethral swabs by using PACE 2: 4.8% (2005), 1.9% (2006) and 2.9% (2007), compared to urine specimen processed by PCR: 1% (2005), 1.4% (2006) and 0% (2007). Even if PCR should be considered a most promising tool for routine diagnosis of Chlamydia infection, Gen Probe allowed us to better identify Chlamydia trachomatis (in 4.8% of urethral swabs compared to urine) leading to a hypothesis that extracellular EB forms of Chlamydia could be absent in urine in persistent infectious.
Collapse
Affiliation(s)
- I Robuffo
- Istituto di Genetica Molecolare, CNR, Sezione di Chieti, Chieti, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008; 19:883-90. [PMID: 18187484 DOI: 10.1093/annonc/mdm585] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We explored the correlation between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their relationship with clinicopathological parameters and their impact on disease-free survival (DFS) and overall survival in early breast cancer patients. PATIENTS AND METHODS This prospective trial included patients with stage I-III breast cancer. Serum HER2 ECD levels were measured by two enzyme-linked immunosorbent assays before surgical treatment. Tissue HER2 status was analyzed by immunohistochemistry (IHC) in all tumors; FISH assay was utilized in HER2 2+ tumors by IHC. RESULTS From May 2000 to July 2005, 256 consecutive stage I-III breast cancer patients were included in this study. High serum HER2 ECD levels (>or=15 ng/ml) were reported in 23 patients (9.0%) and HER2-positive status in tumor tissue was observed in 42 patients (16.4%) with a concordance of 87.1%. High HER2 ECD levels were significantly associated with high histological grade (P = 0.003), stage III (P = 0.008), lymph node involvement (P = 0.035) and negativity of both estrogen (P = 0.016) and progesterone (P = 0.007) receptors. At multivariate analysis, high serum HER2 ECD levels were a significant independent prognostic factor of worse DFS (P = 0.009). CONCLUSIONS A statistically significant association was observed between high serum HER2 ECD levels and worse DFS in early breast cancer patients.
Collapse
Affiliation(s)
- V Ludovini
- Medical Oncology Division, Azienda Ospedaliera of Perugia, Perugia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Bistoni G, Rulli A, Izzo L, Noya G, Alfano C, Barberini F. Nipple-sparing mastectomy. Preliminary results. J Exp Clin Cancer Res 2006; 25:495-7. [PMID: 17310839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Nipple-sparing mastectomy (NSM) combines a skin-sparing mastectomy with preservation of the Nipple Areola Complex (NAC), intraoperative pathological assessment of the nipple tissue core, and immediate reconstruction, thereby permitting better cosmesis for patients undergoing total mastectomy. Radiotherapy of the NAC was carried out in every single patient after surgery. The procedure was first performed on selected patients following a clinical research protocol. From January 2003 to June 2004, 10 patients underwent nipple sparing mastectomy followed by reconstruction (4 of them decided also to undergo a prophylactic mastectomy on the other breast) at the Breast Unit, Policlinico Monteluce, Perugia, Italy. Patients had been accurately selected before the operation following some criteria previously assessed by a team of specialists including the breast surgeon, the oncological physician, the radiotherapist and the plastic surgeon. Histology of the 10 NSMs confirmed invasive carcinoma in 3 cases and in situ carcinoma in the remainder. Superficial necrosis of the NAC that settled down spontaneously without consequences occurred in 2 cases; loss of sensitivity of the NAC in 4 patients; 1 patient developed haematoma. No asymmetry was reported. All women were clear of cancer after the treatment. Nipple-sparing mastectomy is the procedure of choice on selected patients.
Collapse
Affiliation(s)
- G Bistoni
- Plastic Surgery Unit, Department of Surgical, Radiological and Odontostomatological Sciences, University of Perugia, Policlinico Monteluce, Perugia, Italy.
| | | | | | | | | | | |
Collapse
|
7
|
Ludovini V, Gori S, Mosconi A, Pistola L, Rulli E, Rulli A, Anastasi P, Pacifico E, Sidoni A, Tofanetti FR, Colozza M. Evaluation of HER-2 in serum and tissue: correlation with clinical-pathological parameters and outcome in early stage breast cancer (BC) patients (pts). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20066 Background: HER2 is amplified and/or overexpressed in approximately 20–30% of invasive BC and is associated with poor prognosis. It is also a predictive marker of response to trastuzumab. The extracellular domain of the HER2 protein (sHER2) is frequently cleaved and released into the circulation where it can be detected by ELISA in up to 45% of advanced BC. We evaluated HER2 expression in paired serum and tissue samples of operable BC pts to analyze 1) the correlation between sHER2 and HER2 tumor status 2) their relationship with clinical-pathological parameters and 3) their impact on the outcome. Methods: 188 consecutive stage I-III BC pts were included in this study from May 2000 to July 2005. sHER2 was measured by ELISA (manual Kit “Oncogene Science Diagnostics” and automated version “ADVIA Centaur”) before the local treatment. Tumor tissue was analyzed by IHC with CB11 antibody and scored with Dako Hercept-test. HER2 amplification was determined using the Ventana FISH assay in patients with 2+ by IHC. Chi-squared test was used to evaluate the association between HER2 and patients’ clinical-pathological features. Survival outcomes were analyzed using Cox’s model. Results: Median age was 56.6 years; 122 pts received adjuvant chemotherapy, 54 endocrine therapy and 83 both. Forty-three pts (23%) had HER2 overexpression/amplification in tumor tissue and 25 pts (13%) had sHER2 levels ≥15 ng/ml (cut-off level) with a concordance of 85%. Both high sHER2 levels and HER2 tumor expression were associated with high histological grade (p = .02 and p < .0001 respectively) and negativity of ER (p = .0035 and p < .0001) and PgR (p = .0056 and p =. 002). At a median follow-up of 2.4 years we observed 8 deaths and 19 relapses. At univariate analysis high sHER2 levels (evaluated as continuous variable) were significantly correlated with shorter DFS (p = 0.0002) even if at multivariate analysis high sHER2 levels, after adjustment for stage and ER status, were associated with a shorter DFS with borderline significance (p = 0.06). Conclusion: Our preliminary data indicate that the evaluation of sHER2 at diagnosis defines a small subgroup of early BC pts with a poor prognosis even if it needs to be confirmed in a longer follow up. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Ludovini
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - S. Gori
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Mosconi
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - L. Pistola
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - E. Rulli
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Rulli
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - P. Anastasi
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - E. Pacifico
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Sidoni
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - F. R. Tofanetti
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - M. Colozza
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| |
Collapse
|
8
|
Stracci F, La Rosa F, Falsettini E, Ricci E, Aristei C, Bellezza G, Bolis GB, Fenocchio D, Gori S, Rulli A, Mastrandrea V. A population survival model for breast cancer. Breast 2005; 14:94-102. [PMID: 15767178 DOI: 10.1016/j.breast.2004.08.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2004] [Revised: 07/01/2004] [Accepted: 08/18/2004] [Indexed: 11/19/2022] Open
Abstract
Breast cancer is a major health problem, and disease control depends on an effective healthcare system. A registry-based tool to monitor the quality of breast cancer care could be useful. The aim of this study was to develop a population survival model for breast cancer based on the Nottingham Prognostic Model (NPM). To this end, 1452 cases of breast cancer diagnosed in the Umbria Region, Italy, during the period 1994-1996 were studied. An extensive search for routinely available variants in prognosis and treatment was performed. In about 80% of cases complete information on factors included in the NPM was available. The Cox model was used to assess the prognostic value of study factors. Nodal stage was the most important prognostic factor. In women who did not undergo axillary dissection (17%) the risk of death was twice that in women with no affected nodes, but they received chemotherapy with the same frequency. Radiotherapy was also less frequently used in this group. Grading was a significant prognostic factor only when women over 80 were excluded. Population survival models based on data from cancer registries may provide a tool that can be used to evaluate healthcare systems and the effectiveness of interventions. The inclusion of older women in our models decreased the significance of many established prognostic factors because of the frequency of incomplete evaluation and less aggressive treatment in these patients. Not undergoing surgical axillary dissection was associated with a worse prognosis and with less aggressive treatment.
Collapse
Affiliation(s)
- F Stracci
- Department of Hygiene and Public Health, University of Perugia, Umbria Cancer Registry, Via del Giochetto, 06122 Perugia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, Gatti G, D'Aiuto G, Cataliotti L, Paolucci R, Piccolo P, Massaioli N, Sismondi P, Rulli A, Lo Sardo F, Recalcati A, Terribile D, Acerbi A, Rotmensz N, Maisonneuve P. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 2005; 16:383-8. [PMID: 15668261 DOI: 10.1093/annonc/mdi089] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The need to dissect axillary nodes in patients with early breast cancer and clinically negative axilla remains controversial. The aim of the study was to assess the role of axillary radiotherapy (RT) in reducing axillary metastases in patients with early breast cancer who did not receive axillary dissection. PATIENTS AND METHODS From 1995 to 1998, 435 patients over 45 years old with breast cancer up to 1.2 cm and no palpable axillary nodes were randomized 214 to breast conservation without axillary treatment and 221 to breast conservation plus axillary RT. RESULTS After a median follow-up of 63 months, overt axillary metastases were fewer than expected: three cases in the no axillary treatment group (1.5%) and one in the RT group (0.5%). Expected cases were 43 in the no axillary treatment group and 10 in the RT group. Rates of distant metastases and local failures were low, and 5-year disease free survival was 96.0% (95% confidence interval, 94.1%-97.9%) without significant differences between the two arms. CONCLUSIONS This study suggests that occult axillary metastases might never become clinically overt and axillary dissection might be avoided in patients with small carcinomas and a clinically negative axilla. Axillary RT seems to protect the patients from axillary recurrence almost completely.
Collapse
Affiliation(s)
- U Veronesi
- Division of Senology, European Institute of Oncology, Via G. Ripamonti 435, 20141 Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Aristei C, Guerrieri P, Anselmo P, Armellini R, Tarducci R, Rulli A, Latini P, Menghini A. Sister chromatid exchange and micronuclei frequency in early-stage breast cancer patients: preliminary results of a prospective observational study. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)91039-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
11
|
Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, Angelis VD, Crinò L, Tonato M. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004; 90:36-40. [PMID: 14710203 PMCID: PMC2395328 DOI: 10.1038/sj.bjc.6601485] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo. In previous experiences, weekly administration of trastuzumab and paclitaxel has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity and the toxicity of this weekly regimen in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Between November 1999 and July 2001, 25 patients were treated with trastuzumab (4 mg kg−1 i.v. loading dose followed by 2 mg kg−1 i.v. week−1) and paclitaxel (60–90 mg m−2 h−1 i.v. infusion week−1). The treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, after 6 months of therapy, the decision to stop paclitaxel while continuing weekly trastuzumab was left to the physicians' judgement. At the median follow-up of 19.6 months (range 9.2–38.1), all patients are evaluable for response and toxicity. We obtained four (16%) complete responses (CR), 10 (40%) partial responses (PR), four (16%) stable diseases and seven (28%) disease progressions. The response rate (CR+PR) was 56% (95% CI, 36.5–75.5%). The median duration of response was 10.4 months (range 4.1–24.2+). Median time to progression was 8.6 months (range 2.5–24.2+). The toxicity was mild; five patients experienced fever and chills during the first infusion of trastuzumab (20%); leukopenia grade 2 was recorded in one patient (4%). Two patients (8%) came off study for grade 3 cardiotoxicity (after 9 and 17 weeks of treatment, respectively): both had already received anthracyclines and taxanes. Onycholysis grade 2 was observed in five patients (20%). These results confirm that weekly administration of trastuzumab and paclitaxel is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing. Since cardiac disfunctions grade 3 were observed (8%), we recommend that cardiac function should be monitored in these patients.
Collapse
Affiliation(s)
- S Gori
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy. E-mail:
| | - M Colozza
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
| | - A M Mosconi
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
| | - E Franceschi
- Medical Oncology Division, Bellaria Hospital, Via Altura 3, Bologna 40139, Italy
| | - C Basurto
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
| | - R Cherubini
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
| | - A Sidoni
- Institute of Pathological Anatomy and Histology, Division of Cancer Research-Perugia University, Policlinico Monteluce, via Brunamonti 51, Perugia 06122, Italy
| | - A Rulli
- Breast Unit, Surgical Department, Perugia University, Policlinico Monteluce, via Brunamonti 51, Perugia 06122, Italy
| | - C Bisacci
- Breast Unit, Surgical Department, Perugia University, Policlinico Monteluce, via Brunamonti 51, Perugia 06122, Italy
| | - V De Angelis
- Medical Oncology Service, ASL 2 Perugino, Via Piccolotti 1, Marsciano 06055, Italy
| | - L Crinò
- Medical Oncology Division, Bellaria Hospital, Via Altura 3, Bologna 40139, Italy
| | - M Tonato
- Medical Oncology Division, Policlinico Hospital, via Brunamonti 51, Perugia 06122, Italy
| |
Collapse
|
12
|
Bussotti C, Burattini MF, Ricci E, Giuliani N, Bufalari A, Servoli A, Rulli A, Cavazzoni E, Moriconi E, Barberini F. [Rectosigmoid junction neoplasms: our experience]. G Chir 2003; 24:409-12. [PMID: 15018409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The Authors report their experience with 25 patients operated for colorectal junction neoplasms from January 1998 to December 2002 in the Section of Oncological Surgery, at Perugia University. According to the international literature, the Authors maintain the absolute functional and anatomical individuality of this part of the large bowel, underlining the peculiarity of the sigmoidal junction neoplasms respect all the others colic sites regarding clinical manifestations, symptoms developing and biological behaviour. The characteristics seem also capable of changing the surgical choice as well as the prognosis of the disease.
Collapse
Affiliation(s)
- C Bussotti
- Università degli Studi di Perugia, Dipartimento di Scienze Chirurgiche e Medico-Legali Sezione di Chirurgia Generale ed Oncologica
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001; 66:67-72. [PMID: 11368412 DOI: 10.1023/a:1010632919129] [Citation(s) in RCA: 105] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The present work aimed to study the activities of glyoxalase system enzymes, glyoxalase I (G I) and glyoxalase II (G II), as well as the expression of their genes in human breast carcinoma. Samples of tumoral tissue and normal counterparts were drawn from several patients during surgery. They served either for preparing extracts to be used in enzyme activity evaluations or for RNA extraction and subsequent northern blot analysis. A far higher activity level of G I and G II occurs in the tumor compared with pair-matched normal tissue, as shown by both spectrophotometrical assay and electrophoretic pattern. Such increased activities of G I and G II likely result from an enhanced enzyme synthesis as a consequence of increased expression of the respective genes in the tumoral tissue, as evidenced by northern blot. The present findings confirm a key-role of glyoxalase system to detoxify cytotoxic methylglyoxal and modulate S-D-lactoylglutathione levels in tumor cells. Moreover, they suggest a possible employment of GI inhibitors as anti-cancer drugs.
Collapse
Affiliation(s)
- A Rulli
- Department of Surgical Sciences, University of Perugia, Italy
| | | | | | | | | | | | | |
Collapse
|
14
|
Aristei C, Chionne F, Marsella AR, Alessandro M, Rulli A, Lemmi A, Perrucci E, Latini P. Evaluation of level I and II axillary nodes included in the standard breast tangential fields and calculation of the administered dose: results of a prospective study. Int J Radiat Oncol Biol Phys 2001; 51:69-73. [PMID: 11516853 DOI: 10.1016/s0360-3016(01)01595-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE To evaluate if Level I and II axillary nodes are included in the standard breast tangential fields, and to calculate the dose administered. METHODS AND MATERIALS In 35 patients treated with conservative surgery and axillary dissection, three clips were surgically positioned: one at the beginning of Level I, one between Level I and II, and another at the end of Level II. The breast was irradiated with two tangential fields. On simulation films, the volume between the clips was scored as "entirely included" or "not entirely included" in the treatment fields. Computed tomography (CT) scans were performed; CT data were imported into a treatment planning system, and three-dimensional plans were devised. Axillary Levels I and II were delineated on CT slices on the basis of anatomic landmarks. Fields and isodose curves previously obtained were superimposed to calculate the dose administered to the first two axillary node levels and to 90% of both volumes. RESULTS On X-rays, the volume between clips corresponding to Level I was completely included in the medial field in 66.7% of cases and in the lateral field in 63.7% of cases, whereas the volume of Level II was entirely included in the medial field in 54.5% of cases and in the lateral field in 45.4% of cases. The median dose administered to Level I and II was 38.58 Gy +/- 11.01 (range 3.46-47.14) and 20.65 Gy +/- 14.07 (range 0.95-38.94), respectively. The median dose to 90% of both volumes of Level I and II was 6.75 Gy +/- 14.01 (range 1.9-39) and 1.75 Gy +/- 9.72 (range 0.8-29), respectively. CONCLUSION The standard tangential fields do not entirely include Levels I and II axillary nodes.
Collapse
Affiliation(s)
- C Aristei
- Institute of Radiotherapy Oncology, General Hospital and Perugia University, Perugia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Rulli A, Cirocchi R, Vento AR, Naninato P, Zanetti A, Carli L. [Follow-up of surgical biopsies in microcalcifications of the breast. Comparative analysis of patients submitted to mammography and digitalization of mammographic images]. MINERVA CHIR 1997; 52:933-6. [PMID: 9411295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Improvements in the techniques of preoperative needle localization of nonpalpable breast lesions that have been detected at mammography, coupled with surgical biopsy of smaller volumes of breast tissue and the use of local anesthesia have produced a more aggressive attitude toward early biopsy of lesions that are suspected of malignancy. The authors report the follow-up in 92 cases, who underwent breast biopsy for microcalcifications with no palpable lesions. In 46 women the presence of microcalcifications was evaluated through a computerized instrument which allows digitalization of the image.
Collapse
Affiliation(s)
- A Rulli
- Sezione per lo Studio, Diagnosi e Terapia delle Malattie della Mammella, Università degli Studi, Perugia
| | | | | | | | | | | |
Collapse
|
16
|
Rulli A, Cirocchi R, Carli L, Cagini L. [Digital imaging in the surgical detection of breast neoplasms]. G Chir 1993; 14:483-7. [PMID: 8167081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Microcalcific clusters represent good indicators for breast cancer detection. The Authors evaluated 98 cases of breast microcalcifications in patients with no palpable lesions. The patients had undergone mammography, biopsy and excised specimen's radiography to confirm that the target lesion was adequately removed. The presence of microcalcifications was detected through a computerized instrument which allows the digitalization of the image.
Collapse
Affiliation(s)
- A Rulli
- Istituto di Clinica Chirurgica Generale e Terapia Chirurgica, Università degli Studi di Perugia
| | | | | | | |
Collapse
|
17
|
Talpacci A, Destradis E, Rogati L, Rulli A, Tristaino B. [Infectious complications in colo-rectal surgery: how to prevent them?]. MINERVA CHIR 1988; 43:1565-70. [PMID: 3231305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
18
|
Talpacci A, Fabbri C, Rulli A, Giordano G, Tristaino B. [Short-term antimicrobial drug prevention in gastric surgery at high risk for infectious complications]. MINERVA CHIR 1987; 42:895-9. [PMID: 3627496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
19
|
Halabi M, Dutto PH, Rulli A, Gonzalez JA, Pena C. [Strangulated para-esophageal hernia with gastric necrosis. Gastrorraphy. Postoperative massive hemorrhage. Gastrectomy. Recovery]. Prensa Med Argent 1971; 58:1113-6. [PMID: 4938389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|